Evidence map›Paper›PMID 42503702›Full record

ArticleJournal of medicinal chemistry2026

Predicting Ligand Binding Modes by Scaffold-Guided Structure Refinement.

Jonathan Pletzer-Zelgert, Matthias Rarey, Bernd Kuhn

Abstract read
In one paragraph

Article in Journal of medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Jonathan Pletzer-ZelgertUniversity of Hamburg, ZBH - Center for Bioinformatics , Albert-Einstein-Ring 8-10, 22761Hamburg, Germany.ORCID 0009-0000-5545-7129
Matthias RareyUniversity of Hamburg, ZBH - Center for Bioinformatics , Albert-Einstein-Ring 8-10, 22761Hamburg, Germany.ORCID 0000-0002-9553-6531
Bernd KuhnRoche Innovation Center Basel, F. Hoffmann-La Roche Ltd. , Grenzacherstrasse 124, 4070Basel, Switzerland.ORCID 0000-0002-4301-562X

Funding

Roche NA
6 · The paper itself

Abstract

Efficient structure-based drug design relies on knowledge of a ligand's binding pose and its specific interactions─information that is often not available experimentally. Despite the plethora of binding mode prediction methods─including cofolding─achieved accuracies are often insufficient. Here, we present "Scaffold-Guided Structure Refinement", leveraging information on known binders within ligand series targeting a specific protein. Our method is based on the observation that shared molecular scaffolds among binders exhibit conserved binding modes. By applying molecular docking to diverse target model conformations, we identify those simultaneously allowing consistent scaffold placement, favorable interactions and low ligand strain. We demonstrate this approach's ability to optimize models from different initial sources─including an inaccurate cofolding model─in three case studies. In all cases, we successfully identified critical induced fit effects and accurately reconstructed near-native ligand binding modes with scaffold root-mean-square deviation (RMSD) values of at most 2.2 Å.

Indexed as

Drug DesignProteinsBinding SitesLigandsModels, MolecularMolecular Docking SimulationProtein BindingLigandsProteins

Identifiers

PMID42503702
PMCPMC13492369

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.